Canakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes;Canakinumab, un anticuerpo monoclonal frente a IL-1β, con utilidad potencial en distintos procesos inflamatorios

Medicina Clinica

Volumn 136, Issue SUPPL. 1, 2011, Pages 34-37

  Carné, Xavier ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Canakinumab; CAPS; Cryopyrin associated periodic syndromes; IL 1

Indexed keywords

CANAKINUMAB; INTERLEUKIN 1BETA;

AUTOINFLAMMATORY DISEASE; CINCA SYNDROME; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; HUMAN; INFECTION; INFLAMMATION; MIGRAINE; REVIEW; SYMPTOM; VERTIGO;

EID: 79956262871     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/S0025-7753(11)70007-0     Document Type: Article

References (21)

1. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA. 1984;81:7907-11. (Pubitemid 15169171)
2. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002;20:S1-13.
3. Neven B, Callebaut I, Prieur AM, Feldmann J, Bodemer C, Lepore L, et al. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS and FCU. Blood. 2004;103:2809-15.
4. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell. 2006;126:659-62. (Pubitemid 44233635)
5. EMEA. Kineret: Summary of product characteristics. Disponible en: www.emea.europa.eu.
6. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Emery P, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis. 2006;65 Suppl 3:iii2-15.
7. Committee for orphan medicinal products. EMEA/COMP/170868/2008. Disponible en: www.emea.europa.eu.
8. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal- onset multisystem inflammatory disease responsive to interleukin-1 (beta) inhibition. N Engl J Med. 2006;355:581-92. (Pubitemid 44200651)
9. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Artritis Rheum. 2008;58:2443-52.
10. Novartis AG Press Release. ACZ885 phase III data show rapid, sustained clinical remission in children and adults suffering from a group of rare, potentially life-threatening autoinflammatory diseases. Novartis AG Press Release 2008 October 27.
11. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, et al. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J Exp Med. 2009;206:1029-36.
12. J. Bonner, P. Lloyd, P. Lowe, G. Golor, R. Woessner, S. Pascoe, et al. PK/PD, safety and tolerability of a human anti-IL1β monoclonal antibody (ACZ885) in healthy subjects. Annu Congr Eur Resp Soc. 2006 september; 02-06.Abs748.
13. Alten R, Gram H, Joosten MA, van den Berg WB, Sieper J, Wassenberg S, et al. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R67-75.
14. Church LD, McDermott MF. Canakinumab, a fully human mAb against IL1β for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009;11:81-9.
15. N Ruperto, P Quartier, N Wulffraat, P Woo, A Loy, R Mouy, et al. ACZ885 (canakinumab) a new IL-1β blocking monoclonal antibody, has a beneficial effect in children with systemic juvenile idiopathic arthritis (SJIA). Artritis Rheum. 2008;58:9 Suppl: S633.
16. Lachmann HJ, Jung T, Felix S, Lowe P, Offer M, Rord Ford C, et al. Treatment of cryopyrin-associated periodic fever syndrome with a fully human anti-IL-1β monoclonal antibody (ACZ885): results from a subcutaneous administration study. Clin Exp Rheumatol. 2008; 26:181.
17. Lachmann HJ, Jung T, Bobadilla M, Felix SD, Woessner R, Leslie KS, et al. Treatment of Muckle ells syndrome with a fully human anti-IL-1Beta monoclonal antibody (ACZ885). Initial results from a proof. of concept study. Ann Rheum Dis 2006;65 (Suppl II):76.
18. Kümmerle-Deschner JB, Tzaribachev N, Koetter I, Hansmann S, Granlich K, Felix SD, et al. Long lasting response to ACZ885 in patients with Muckle-Wells-syndrome. Ann Rheum Dis 2008;67 (Suppl II):104.
19. J Kümmerle-Deschner, N Blank, J Roesler, E Ramos, N Tzaribachev, K Gramlich, et al. Canakinumab (ACZ885), a new IL1-β blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS). Artritis Rheum. 2008;58 9 Suppl:S614.
20. H. Lachman, I. Kone-Paut, J. Kuemmerle-Deschner, K. Leslie, E. Hachulla, P. Quartier, et al. Efficacy and safety of canakinumab (ACZ885), a fully human antiinterleukin- 1β antibody, in cryopyrin-associated periodic fever syndrome: Results of a multicenter, randomized, double-blind, phase III study. Am Coll Rheumatol. 2008 October 27 Abs L1.
21. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier E, et al. Use of canakinumab in the cryopyrin-associated syndrome. N Engl J Med. 2009;360:2416-25.